Telomir Pharmaceuticals (NASDAQ: TELO) has announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that Telomir-Zn, the company’s lead therapeutic candidate, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The findings, which include reduced oxidative stress, lower hepatic copper burden, and improved liver function markers, support the biological activity of Telomir-Zn in Wilson’s disease and expand the company’s scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation.
Wilson’s disease is a genetic disorder characterized by excessive copper accumulation in the body, primarily affecting the liver and brain. Current treatments focus on chelation therapy or zinc acetate to reduce copper levels, but they often come with significant side effects and limited efficacy. The preclinical data suggest that Telomir-Zn may offer a novel approach by modulating intracellular metal homeostasis and redox balance, potentially addressing underlying disease mechanisms.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The publication of these data in a peer-reviewed journal adds credibility to Telomir’s platform and could accelerate interest in the drug’s broader applications. For investors, this development diversifies the company’s pipeline beyond oncology, potentially opening a new therapeutic avenue for a rare disease with unmet medical needs. The news also highlights the versatility of Telomir-Zn’s mechanism, which may have implications for other conditions linked to metal dyshomeostasis and oxidative stress.
For more information on the latest news and updates relating to Telomir Pharmaceuticals, visit the company’s newsroom at https://ibn.fm/TELO.
